Office of National Drug Control Policy Reauthorization Act of 2024
This bill reauthorizes through FY2031 the Office of National Drug Control Policy and related grants, programs, and initiatives such as
[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9598 Introduced in House (IH)]
<DOC>
118th CONGRESS
2d Session
H. R. 9598
To amend the Office of National Drug Control Policy Reauthorization Act
to reauthorize such Office, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 16, 2024
Mr. Comer (for himself, Mr. Raskin, Mr. Duarte, Mr. Nadler, Mrs.
Gonzalez-Colon, and Ms. Plaskett) introduced the following bill; which
was referred to the Committee on Oversight and Accountability, and in
addition to the Committees on the Judiciary, and Energy and Commerce,
for a period to be subsequently determined by the Speaker, in each case
for consideration of such provisions as fall within the jurisdiction of
the committee concerned
_______________________________________________________________________
A BILL
To amend the Office of National Drug Control Policy Reauthorization Act
to reauthorize such Office, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Office of National Drug Control
Policy Reauthorization Act of 2024''.
SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION.
(a) Amendments to the Office of National Drug Control Policy
Reauthorization Act of 1998.--The Office of National Drug Control
Policy Reauthorization Act of 1998 (21 U.S.C. 1701 et seq.) is
amended--
(1) in section 702 (21 U.S.C. 1701)--
(A) in paragraph (2)(A)(ii), by striking
``Government Reform'' and inserting ``Accountability'';
(B) in paragraph (3)--
(i) in subparagraph (L), by striking ``;
and'' and inserting a semicolon;
(ii) in subparagraph (M), by striking the
period at the end and inserting ``; and''; and
(iii) by adding at the end the following:
``(N) tertiary prevention support or services,
including opioid antagonists or overdose reversal
agents such as naloxone, and other harm reduction
activities such as overdose and drug detection
testing.'';
(C) by amending paragraph (7) to read as follows:;
``(7) Emerging drug threat.--The term `emerging drug
threat' means the occurrence of a new and growing trend in the
illicit use or misuse of a drug, class of drugs, or non-
controlled substance, or a new or evolving method of drug
consumption or trafficking, including rapid expansion in the
supply of or demand for such a drug or substance.'';
(D) in paragraph (9), by striking ``drug laws'' and
inserting the following: ``drug, trade, and illicit
drug trafficking laws'';
(E) in paragraph (10), by inserting after ``demand
reduction,'' the following: ``illicit drug
trafficking,'';
(F) by redesignating paragraphs (15), (16), and
(17) as paragraphs (17), (18), and (19), respectively;
(G) by inserting after paragraph (14) the following
new paragraph:
``(15) Precursor chemical.--
``(A) In general.--The term `precursor chemical'
includes a listed chemical and an unregulated
precursor.
``(B) Listed chemical.--The term `listed chemical'
has the meaning given that term in section 102 of the
Controlled Substances Act (21 U.S.C. 802).
``(C) Unregulated precursor.--The term `unregulated
precursor'--
``(i) means any chemical used in the
production of illicit drugs that has not been
identified as a listed chemical under the
Controlled Substances Act; and
``(ii) does not include a solvent or
reagent.
``(16) State.--The term `State' means each of the several
States of the United States, the District of Columbia, and each
territory or possession of the United States.'';
(H) in paragraph (19), as so redesignated--
(i) by redesignating subparagraphs (G) and
(H) as subparagraphs (H) and (I), respectively;
and
(ii) by inserting after subparagraph (F)
the following:
``(G) activities to map, track, dismantle, and
disrupt the financial enablers of drug trafficking
organizations, transnational criminal organizations,
and money launderers involved in the manufacture and
trafficking of drugs in the United States and in
foreign countries;''; and
(I) by inserting at the end the following:
``(20) United states.--The term `United States', when used
in a geographical sense, means all of the States, the District
of Columbia, and the territories and possessions of the United
States, and any waters within the jurisdiction of the United
States.
``(21) Evidence.--The term `evidence' has the meaning given
that term in section 3561 of title 44, United States Code.'';
(2) in section 703(d) (21 U.S.C. 1702(d))--
(A) in paragraph (5)(B), by striking ``accepted by
a contractor to be used in its performance of a
contract for the Office'' and inserting the following:
``accepted--
``(i) by a contractor (or subcontractor
thereof at any tier) for use in its performance
of a contract for the Office; or
``(ii) by a grant recipient (or subgrantee
thereof at any tier) for use in carrying out an
award related to a fund administered by the
Office.''; and
(B) in paragraph (6), by inserting after
``paragraph (5)'' the following: ``and the registry
shall be sent to the appropriate Congressional
committees'';
(3) in section 704 (21 U.S.C. 1703)--
(A) in subsection (a)(1)(C), by striking ``shall''
and inserting ``may'';
(B) in subsection (b)--
(i) in paragraph (16), by inserting after
``to treat addiction'' the following: ``,
encourage primary substance use prevention, and
increase accessibility and effectiveness of
life-saving opioid antagonists or reversal
agents, such as naloxone'';
(ii) by striking paragraph (20);
(iii) by redesignating paragraph (21) as
paragraph (20);
(iv) in paragraph (20), as so redesignated,
by striking the period at the end and inserting
``; and''; and
(v) by inserting at the end the following:
``(21) shall coordinate with the Secretary of Homeland
Security, the Attorney General, and the Secretary of State
regarding the status of the enforcement of clauses (i) and (ii)
of subparagraph (A) and subparagraph (B) of section 237(a)(2)
(8 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C) of section
212(a)(2) (8 U.S.C. 1182(a)(2)) for the purposes of ensuring
such drug control and illicit drug trafficking enforcement
activities are adequately resourced.'';
(C) in subsection (c)--
(i) in paragraph (1)(C), by striking
``supply reduction, and State, local, and
tribal affairs, including any drug law
enforcement activities'' and inserting the
following: ``supply reduction, accessibility to
life-saving opioid antagonists or reversal
agents, such as naloxone, and State, local, and
Tribal affairs, including any drug related law
enforcement activities'';
(ii) in paragraph (3)(C)--
(I) in clause (ii), by inserting
after ``United States'' the following:
``, including at and between the ports
of entry,'';
(II) in clause (iii), by striking
``; and'' and inserting a semicolon;
(III) in clause (iv), by striking
the period at the end and inserting ``;
and''; and
(IV) by inserting at the end the
following new clause:
``(v) requests funding for activities that
facilitate illicit drug use, but not including
overdose reversal medications, drug checking,
or testing technology.'';
(D) in subsection (d)(8)(F)(ii), by striking ``and
at United States ports of entry by officers and
employees of National Drug Control Program agencies and
domestic and foreign law enforcement officers'' and
inserting the following: ``and at and between United
States ports of entry by officers and employees of
National Drug Control Program agencies and domestic and
foreign law enforcement officers'';
(E) in subsection (i)--
(i) in paragraph (1)(A), by striking ``to
address illicit drug use issues'' and inserting
the following: ``to address illicit drug use,
prevention and treatment of overdose and
addiction, and law enforcement activities'';
and
(ii) in paragraph (2), by striking ``2023''
and inserting ``2031''; and
(F) in subsection (k)--
(i) in the heading, by striking ``Harm
Reduction Programs'' and inserting ``Substance
Use Prevention, Harm Reduction, and Life-Saving
Treatment Programs''; and
(ii) in the first sentence, by inserting
after ``drug addiction and use'' the following:
``with the primary goal being the prevention of
initial or continued use and the fostering of
life-saving opioid antagonists or reversal
agents, such as naloxone'';
(4) in section 705 (21 U.S.C. 1704)--
(A) in subsection (a)(3)--
(i) in subparagraph (A), by inserting after
``Federal Government'' the following: ``and
such lands owned by a foreign principal (as
such term in defined in section 1(b) of the
Foreign Agents Registration Act of 1938 (22
U.S.C. 611))'';
(ii) in subparagraph (B)--
(I) by inserting after ``the
preceding year'' the following: ``,
along with historical comparisons over
the prior 20 years,'';
(II) in clause (i)--
(aa) by inserting after
``seizing drugs,'' the
following: ``including
precursor chemicals,''; and
(bb) by striking ``; and''
and inserting a semicolon;
(III) in clause (ii), by striking
the period at the end and inserting ``;
and''; and
(IV) by inserting at the end the
following new clause:
``(iii) the effects of trends of encounters
of inadmissible aliens at and between the ports
of entry, and the effect of any increases or
changes in the level of trade and travel, on
the capacity and ability of the Department of
Homeland Security components to interdict and
prevent the unlawful entry of illicit drugs
into the United States by any means.''; and
(iii) in subparagraph (D)--
(I) by inserting after ``the
preceding year'' the following: ``,
along with historical comparisons over
the prior 20 years,''; and
(II) in clause (iii), by inserting
after ``seizing drugs,'' the following:
``including precursor chemicals,'';
(B) in subsection (e)(2), by inserting before the
period at the end the following: ``and $3,000,000 for
each of fiscal years 2025 through 2031''; and
(C) in subsection (f)--
(i) in paragraph (2), by inserting after
``agency shall'' the following: ``, in
accordance with guidelines issued by the
Director for standard definitions,
identification, and review procedures,''; and
(ii) by striking paragraph (4);
(5) in section 706 (21 U.S.C. 1705)--
(A) in subsection (c)--
(i) in paragraph (1)--
(I) by striking subparagraph (D);
(II) in subparagraph (H)--
(aa) by inserting after
``identifying existing'' the
following: ``evidence,''; and
(bb) by striking ``will
obtain such data'' and
inserting ``will ensure such
data is obtained'';
(III) in subparagraph (J)(ii), by
inserting ``evidence,'' before
``data'';
(IV) in subparagraph (L), by
inserting ``evidence'' after ``Such
other''; and
(V) in subparagraph (M)(iv), by
inserting ``storing and retrieving,''
after ``collecting,'';
(ii) in paragraph (2)--
(I) by redesignating subparagraphs
(E) and (F) as subparagraphs (G) and
(H), respectively; and
(II) by inserting after
subparagraph (D) the following new
subparagraphs:
``(E) The Administrator of the Office of
Information and Regulatory Affairs.
``(F) The Chief Data Officers Council.'';
(iii) in paragraph (3)--
(I) in subparagraph (B)(ii)--
(aa) in subclause (I), by
striking ``; and'';
(bb) in subclause (II), by
striking the period at the end
and inserting ``; and''; and
(cc) by inserting at the
end the following new
subclause:
``(III) an analysis of the effects
of trends of encounters of inadmissible
aliens at and between the ports of
entry, and the effect of any increases
or changes in the level of trade and
travel, on the capacity and ability of
the Department of Homeland Security to
interdict and prevent the unlawful
entry of illicit drugs into the United
States by any means.''; and
(II) by adding at the end the
following new subparagraph:
``(D) Requirement for caribbean border
counternarcotics strategy.--
``(i) Purposes.--The Caribbean Border
Counternarcotics Strategy shall--
``(I) set forth the strategy of the
Federal Government for preventing the
illegal trafficking of drugs through
the Caribbean region into the United
States, including through ports of
entry, between ports of entry, and
across air and maritime approaches;
``(II) state the specific roles and
responsibilities of each relevant
National Drug Control Program agency
for implementing the strategy;
``(III) identify the specific
resources required to enable the
relevant National Drug Control Program
agencies to implement the strategy, to
the extent practicable; and
``(IV) be designed to promote, and
not hinder, legitimate trade and
travel.
``(ii) Specific content related to puerto
rico and the united states virgin islands.--The
Caribbean Border Counternarcotics Strategy
shall include--
``(I) a strategy to prevent the
illegal trafficking of drugs to or
through Puerto Rico and the United
States Virgin Islands, including
measures to substantially reduce drug-
related violent crime on such islands;
and
``(II) recommendations for
additional assistance or authorities,
if any, needed by Federal, State, and
local law enforcement agencies relating
to the strategy, including an
evaluation of Federal technical and
financial assistance, infrastructure
capacity building, and interoperability
deficiencies.''; and
(iv) in paragraph (5), by striking ``data''
each place it appears and inserting ``evidence,
data,'';
(B) in subsection (f)--
(i) in paragraph (1), by striking
``publicly available in a machine-readable
format'' and inserting the following:
``publicly available as an open Government data
asset (as such term is defined in section 3502
of title 44, United States Code)'';
(ii) in paragraph (2), by inserting after
``searchable format'' the following:
``available for bulk download to the extent
practicable''; and
(iii) by amending paragraph (3) to read as
follows:
``(3) Data.--The data included in the Drug Control Data
Dashboard shall be updated annually with final data, and to the
extent practicable, updated quarterly with provisional data,
that aligns with the goals of the performance measurement
system required under subsection (h) and include, at a minimum,
the following:
``(A) For each substance identified by the Director
as having a significant impact on illicit drug use in
the United States, data sufficient to--
``(i) assess supply reduction efforts,
including, to the extent practicable, the total
amount of substances seized;
``(ii) assess drug use behaviors;
``(iii) estimate the prevalence of
substance use disorders;
``(iv) show the number of fatal and non-
fatal overdoses; and
``(v) assess the provision of substance use
disorder treatment.
``(B) Any quantifiable measures the Director
determines to be appropriate to detail progress toward
the achievement of the goals of the National Drug
Control Strategy, including, to the extent practicable,
data disaggregated by specific geographic areas or sub-
populations of interest.
``(C) Data sufficient to assess the effectiveness
of such substance use disorder treatments.
``(D) To the extent practicable, data sufficient to
show the extent of prescription drug diversion,
trafficking, and misuse in the calendar year and each
of the previous 3 calendar years.
``(E) Any quantifiable measures the Director
determines to be appropriate to detail progress toward
the achievement of the goals of the National Drug
Control Strategy, including to the extent practicable,
data disaggregated by specific geographic areas or sub-
populations of interest.''; and
(C) in subsection (g)(2)--
(i) in subparagraph (D), by striking
``narcotics'' and inserting ``drugs'';
(ii) in subparagraph (E), by striking
``drug use'' and inserting ``illegal drug
use''; and
(iii) in subparagraph (F), by striking
``drug use'' and inserting ``illegal drug
use'';
(6) in section 707 (21 U.S.C. 1706)--
(A) in subsection (l)(2)(F), by inserting ``and
authorities enforcing illicit drug trafficking laws''
after ``task forces'';
(B) in subsection (m)(2), by inserting ``,
authorities enforcing illicit drug trafficking laws,''
after ``agencies'';
(C) in subsection (p)--
(i) in paragraph (5). by striking ``; and''
and inserting a semicolon;
(ii) in paragraph (6), by striking the
period at the end and inserting ``; and''; and
(iii) by inserting at the end the following
new paragraph:
``(7) $298,579,000 for each of fiscal years 2025 through
2031.'';
(D) in subsection (s)--
(i) in the matter before paragraph (1), by
striking ``The Director'' and inserting
``Except as provided in subsection (t)(2), the
Director'';
(ii) in paragraph (2), by striking ``;
and'' and inserting a semicolon;
(iii) in paragraph (3), by striking the
period at the end and inserting ``; and''; and
(iv) by adding at the end the following:
``(4) enhancing fentanyl seizure and interdiction
activities.''; and
(E) by adding at the end the following:
``(t) Supplemental Grants for Fentanyl Interdiction Activities.--
``(1) Minimum allocation of funds for fentanyl interdiction
activities.--Of the amounts allocated for grants under
subsection (s), not less than $5,000,000 shall be allocated for
the purpose of making grants under subsection (s)(4).
``(2) Additional funds.--In addition to amounts allocated
under subparagraph (A) for the purpose of making grants under
subsection (s)(4), the Director may use amounts otherwise
appropriated to carry out this section for such purpose.
``(u) Additional Judiciary Prosecutorial Resources.--
``(1) Temporary reassignment of assistant united states
attorneys.--
``(A) Authority.--The Attorney General may identify
assistant United States attorneys who may be made
available for temporary reassignment under subsection
(b)(2) for a period of time determined by the Attorney
General in coordination with the Director, during which
an assistant United States attorney shall prioritize
the investigation and prosecution of organizations and
individuals trafficking in fentanyl or fentanyl
analogues.
``(B) Extension of reassignment.--Such reassignment
may be extended by the Attorney General for such time
as may be necessary to conclude any ongoing
investigation or prosecution in which the assistant
United States attorney is engaged.
``(2) Process for temporary reassignment.--The Attorney
General may establish a process under which the Director, in
consultation with the Executive Boards of each designated high
intensity drug trafficking area, may request such an assistant
United States attorney to be so temporarily reassigned.
``(v) Use of Funds To Combat Fentanyl Trafficking.--
``(1) Requirement.--As part of the documentation that
supports the President's annual budget request for the Office,
the Director shall submit to Congress a report describing the
use of HIDTA funds for the purposes of enhancing fentanyl
seizure and interdiction activities under subsection (s)(4) or
(t) and to investigate and prosecute organizations and
individuals trafficking in fentanyl or fentanyl analogues in
the prior calendar year.
``(2) Contents.--The report shall include--
``(A) the amounts of fentanyl or fentanyl analogues
seized by HIDTA-funded initiative in the area during
the previous year; and
``(B) law enforcement intelligence and predictive
data from the Drug Enforcement Administration showing
patterns and trends in abuse, trafficking, and
transportation in fentanyl and fentanyl analogues.
``(w) Report on Data Analytical Services Program.--
``(1) Report.--With respect to the Data Analytical Services
program (formally known as Hemisphere), and any successor
program, the Director shall submit to the Committee on
Oversight and Accountability and the Committee on the Judiciary
of the House of Representatives, and the Committee on the
Judiciary of the Senate a report every two years on any
activities of the program--
``(A) funded by the Office; and
``(B) carried out in two years prior to the
submission of the report.
``(2) Contents of report.--The report required by paragraph
(1) shall include the following:
``(A) A documentation of any activities of the Data
Analytical Services program, including--
``(i) the amount of searches conducted for
each HIDTA; and
``(ii) each requesting local law
enforcement jurisdiction.
``(B) Information on how the program was funded and
how funds were expended under the program, including
information on any--
``(i) funding sources derived from each
HIDTA's funding allocation for a HIDTA, or any
other source of funding, for the program; and
``(ii) payments made by the program to any
non-governmental entity or external vendor.
``(C) A description of any policies and guidelines
provided to HIDTA personnel and local law enforcement
jurisdictions governing the operation of the program in
order to ensure that such program does not infringe on
rights protected under the Fourth Amendment or violate
legally protected privacy of United States citizens or
individuals legally in the United States, along with
any recommendations by the Director to strengthen such
policies and guidelines.'';
(7) in section 709(f)(1) (21 U.S.C. 1708(f)(1)), by
striking ``shall'' and inserting ``may'';
(8) in section 709 (21 U.S.C. 1708)--
(A) in subsection (f)(2)(B)(iii), by inserting
after ``professionals'' the following: ``including
experts in evidence-based media campaigns, education,
and evaluation''; and
(B) in subsection (g), by striking ``2023'' and
inserting ``2031'';
(9) in section 711 (21 U.S.C. 1710), including the
headings, by striking ``Command and Control Plan'' each place
it appears and inserting ``Strategic Plan''; and
(10) in section 714 (21 U.S.C. 1711), by inserting before
the period at the end the following: ``and $20,000,000 for each
of fiscal years 2025 through 2031''.
(b) Amendments to the Anti-Drug Abuse Act of 1988.--The Anti-Drug
Abuse Act of 1988 (Public Law 100-690) is amended--
(1) in section 1024(a) (21 U.S.C. 1524(a)), by inserting
before the period at the end the following: ``and $109,000,000
for each of fiscal years 2025 through 2031''; and
(2) in section 1032(b) (21 U.S.C. 1532(b))--
(A) by striking ``$125,000'' each place the term
appears and inserting ``$150,000''; and
(B) in paragraph (3)--
(i) by striking subparagraph (A) and
inserting the following:
``(A) In general.--Subject to subparagraph (F), the
Administrator may award up to 2 additional grants under
this paragraph to an eligible coalition awarded a grant
under paragraph (1) or (2) for any first fiscal year
after the end of the 4-year or 9-year period following
the period of the initial or subsequent grant under
paragraph (1) or (2), as the case may be.'';
(ii) in subparagraph (B), by striking ``a
renewal grant'' and inserting ``up to 2 renewal
grants'';
(iii) in subparagraph (C), by striking ``an
additional grant'' and inserting ``the
additional grants''; and
(iv) by striking subparagraph (D) and
inserting the following:
``(D) Renewal grants.--Subject to subparagraph (F),
the Administrator may award a renewal grant to a grant
recipient under this paragraph for each fiscal year of
the 4-fiscal-year period following the first fiscal
year for which an additional grant under this paragraph
is awarded in an amount not to exceed the amount of
non-Federal funds raised by the coalition, including
in-kind contributions, for that fiscal year.''.
(c) Reauthorization of the National Community Anti-Drug Coalition
Institute.--Section 4(d) of Public Law 107-82 (21 U.S.C. 1521 note) is
amended by striking ``section 1032 of the National Narcotics Leadership
Act of 1988 (15 U.S.C. 1532), make a grant of $2 million under
subsection (a), for each of the fiscal years 2018 through 2023'' and
inserting ``section 1024 of the National Narcotics Leadership Act of
1988 (21 U.S.C. 1524), make a grant of $2,500,000 under subsection (a),
for each of the fiscal years 2025 through 2031''.
(d) Reauthorization of Community-Based Coalition Enhancement Grants
To Address Local Drug Crises.--Subsection (i) of section 103 of the
Comprehensive Addiction and Recovery Act of 2016 (21 U.S.C. 1536) is
amended by inserting before the period at the end the following: ``and
$5,200,000 for each of fiscal years 2025 through 2031''.
(e) Report Regarding Life-Saving Opioid Antagonists or Reversal
Agents.--The Office of National Drug Control Policy Reauthorization Act
of 2006 (Public Law 109-469) is amended by adding at the end the
following new section:
``SEC. 1121. REQUIREMENT FOR LIFE-SAVING OPIOID OVERDOSE REVERSAL
STUDY.
``(a) Finding.--Congress finds that it is vital to support access
to treatment and emergency intervention tools to address drug addiction
while also pursuing strategies to ensure communities have readily
available access to life-saving drug overdose reversal medications,
including opioid antagonists or reversal agents, such as naloxone, in
case of an emergency.
``(b) Report.--Not later than 180 days after the date of the
enactment of this section, the Director of the Office of National Drug
Control Policy shall submit to Congress a report that contains the
following:
``(1) A summary of the relevant roles, responsibilities,
and authorities of each relevant National Drug Control Program
agency to ensure that life-saving drug overdose reversal
medications are readily available in case of an emergency,
including life-saving opioid antagonists or reversal agents,
such as naloxone, across the Nation.
``(2) A strategy for the Federal Government to ensure that
State, local, and Tribal governments, and agencies thereof
including law enforcement and public health and safety
entities, have life-saving drug overdose reversal medications
readily available in case of an emergency, including life-
saving opioid antagonists or reversal agents, such as naloxone,
which at a minimum identifies--
``(A) any Federal and State policies and actions
necessary for the relevant National Drug Control
Program agencies to take to address--
``(i) the challenges faced by pharmacists,
prescription drug providers, dispensers
(including manufacturers, distributors, and
retailers), and other health care providers, to
make such medications readily available to
patients over the counter for emergency use;
``(ii) the challenges faced by pharmacists,
health care providers, and State health
officials to educate the public on the risks
and benefits of such medications, including how
to effectively use such medications; and
``(iii) the appropriate training of State
and local health care providers and first
responders on the use of such medications; and
``(B) identifies any budgetary resources, personnel
resources, licensing requirements, and legal
authorities that relevant National Drug Control Program
agencies needs to enable the availability of such life-
saving emergency drug overdose medications;
``(3) A summary of policies in effect before the submission
of the report that are administered by--
``(A) the Director of the Office National Drug
Control Policy;
``(B) the Secretary of Health and Human Services;
and
``(C) each National Drug Control Program agency, as
applicable.
``(4) A summary of the specific actions taken over the
previous 10 years before the submission of the report by the
Substance Abuse and Mental Health Services Administration and
the Drug Enforcement Administration to coordinate with one
another and with State health agencies to ensure that--
``(A) such treatments, including medications, are
accessible to the public; and
``(B) appropriate public education on the use of,
and the risks and benefits of, such treatments,
including medications, are readily available.
``(c) Updates.--Any significant update made to the strategy
included in the report required by paragraph (2)(B) after such report
is submitted shall be included in the next National Drug Control
Strategy submitted to Congress after such update is made.''.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Oversight and Accountability, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Oversight and Accountability, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Oversight and Accountability, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Committee Consideration and Mark-up Session Held
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 38 - 0.
Mr. Comer moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H6319-6324)
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line
DEBATE - The House proceeded with forty minutes of debate on H.R. 9598.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H6395-6396)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 399 - 1 (Roll no. 485). (text: 12/4/2024 CR H6319-6322)
Roll Call #485 (House)On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 399 - 1 (Roll no. 485). (text: 12/4/2024 CR H6319-6322)
Roll Call #485 (House)Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on the Judiciary.